Literature DB >> 6621082

Reoperation on prosthetic heart valves. An analysis of risk factors in 552 patients.

D G Husebye, J R Pluth, J M Piehler, H V Schaff, T A Orszulak, F J Puga, G K Danielson.   

Abstract

Five hundred fifty-two patients underwent a total of 617 reoperations for repair or replacement of a prosthetic heart valve. Operative mortality for first reoperation (530 patients) was 5.9% for the aortic position and 19.6% for the mitral position. Overall operative mortality was 14% for second reoperation (69 patients) and 7% for third reoperation (14 patients). In addition to valve position, operative mortality for first reoperation appeared to be related to pre-reoperation functional class and urgency of operation. First reoperation for mitral valve patients in New York Heart Association (NYHA) Class II was 4.2%; for Class III, 9.3%; and for Class IV, 41%. In the aortic position, operative mortality was 2.4% for Class I, 1.6% for Class II, 6.3% for Class III, and 20.8% for Class IV. The mortality for elective mitral valve reoperation was 0%; for urgent operation, 20.3%; and for emergency procedures, 54.5%. Elective aortic valve reoperation carried a 1.4% mortality; urgent procedures, 8%; and emergency procedures, 37.5%. No significant differences in bleeding complications were noted between reoperations and initial valve replacement. The data appear to suggest that when significant valve dysfunction is first noted, reoperation should be undertaken to minimize operative risk.

Entities:  

Mesh:

Year:  1983        PMID: 6621082

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  16 in total

1.  Replacement of a Björk-Shiley Delrin aortic valve still functioning after 25 years.

Authors:  M Ismail Badak; Erdem Ali Ozkisacik; Mehmet Boga; Ugur Gurcun; Berent Discigil
Journal:  Tex Heart Inst J       Date:  2004

2.  Thrombolytic therapy for prosthetic pulmonary valve thrombosis.

Authors:  Peter Schott; Karl Heinrich Scholz
Journal:  Clin Res Cardiol       Date:  2006-06-13       Impact factor: 5.460

3.  Second and third cardiac valve reoperations: factors influencing death and long-term survival.

Authors:  Mehmet Erdem Toker; Ercan Eren; Mustafa Guler; Kaan Kirali; Mehmet Yanartas; Mehmet Balkanay; Cevat Yakut
Journal:  Tex Heart Inst J       Date:  2009

Review 4.  Current status of anticoagulation and thrombosis-related issues in mechanical valves.

Authors:  R J Gray
Journal:  Tex Heart Inst J       Date:  1996

5.  Fibrinolytic therapy for mechanical pulmonary valve thrombosis.

Authors:  Zahra Khajali; Shabnam Mohammadzadeh; Majid Maleki; Mohammad Mehdi Peighambari; Anita Sadeghpoor; Alireza Ghavidel; Behrad Elahi; Mohammadreza Mirzaaghayan
Journal:  Pediatr Cardiol       Date:  2014-08-22       Impact factor: 1.655

6.  Intermittently stuck occluder: case report of an unusual complication with the use of an aortic Omniscience prosthesis.

Authors:  S Nawa; S Ohsumi; K Kurozumi; H Izumoto; Y Nakayama; M Shigenobu; E Sugawara; Y Senoo; S Teramoto
Journal:  Heart Vessels       Date:  1987       Impact factor: 2.037

7.  Risk factors for short- and long-term survival in patients undergoing re-replacement due to prosthetic valve dysfunction.

Authors:  Bilgehan Savaş Oz; Hikmet Iyem; Hakki Tankut Akay; Cengiz Bolcal; Mehmet Yokusoglu; Erkan Kuralay; Ufuk Demirkilic; Harun Tatar
Journal:  Heart Vessels       Date:  2006-11-27       Impact factor: 2.037

8.  Rapidly deteriorated failure of Carpentier-Edwards porcine bioprosthesis caused by three detached commissures: report of a case.

Authors:  Y Terada; Y Wanibuchi
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

9.  Early massive thrombosis of a mechanical mitral valve.

Authors:  P Masiello; G Mastrogiovanni; G Santoro; S Iesu; G Di Benedetto
Journal:  Tex Heart Inst J       Date:  1998

10.  The risks of reoperation for prosthetic valve dysfunction.

Authors:  Y Kawachi; K Matuzaki; R Tominaga; H Yasui; K Tokunaga
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.